Prevention of Respiratory Syncytial Virus Infection: From Vaccine to Antibody
| Autor: | Kelly J. Huang, Herren Wu |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Microbiology (medical)
Palivizumab Physiology viruses Disease Respiratory Syncytial Virus Infections Antibodies Viral Chemoprevention Virus Genetics Respiratory Syncytial Virus Vaccines Medicine Humans Adverse effect General Immunology and Microbiology Ecology biology business.industry Vaccination Antibodies Monoclonal Immunoglobulins Intravenous Cell Biology Virology Respiratory Syncytial Viruses Infectious Diseases Infectious disease (medical specialty) Immunology biology.protein Antibody business medicine.drug |
| Zdroj: | Microbiology spectrum. 2(4) |
| ISSN: | 2165-0497 |
| Popis: | Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract disease in infants and young children. Initial efforts to develop a vaccine to prevent RSV lower respiratory tract disease in children were halted because of serious adverse events that occurred when children were infected with RSV following vaccination, including vaccine-related deaths. Subsequently, a major focus for researchers was to understand what led to these adverse events. Investment in a vaccine for RSV continues, and new strategies are under development. Success to prevent RSV disease was met by the development of immunoprophylaxis, first with intravenous immunoglobulin and then with recombinant monoclonal antibody. The story of immunoprophylaxis for RSV includes the first-in-class use of antibody technology for infectious disease, and palivizumab currently remains the only way to prevent serious lower respiratory tract disease due to RSV infection. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|